No abstract available.
Growth Disorders* ; Insulin-Like Growth Factor Binding Proteins* ; Somatomedins*

OBJECTIVE: The purpose of this study was to investigate possible menopause related changes in circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and their relationship with insulin-like growth factor 1 (IGF-1) plasma levels, osteocalcin(Ost) and urinary deoxypyridinoline(Dpd) in either surgical menopause or natural menopause, METHOD: Seventy-two postmenopausal women (surgical menopause 48, natural menopause 24) were invited to participate in this study. In all subjects plasma IGF-1 and IGFBP-3 levels were measSURED by radioimmunoassay and Ost and Dpd were measured by enzyme linked immunosorbent assay(ELISA). RESULTS: No difference was found between mean IGFBP-3 plasma levels in the two groups studied(3,522 +/- 926 vs 3,854 +/- 569 ng/ml), while mean IGF-1 levels were significantly lower in natural menopause as compared with surgical menopause (natural 126 +/- 44 vs surgical 163 +/- 66 ng/ml, p=0.007). No difference was found between mean Ost levels in the two groups studied (natural menopause 8.0 +/- 2.9 vs surgical menopause 8,9 +/- 2.1 ng/ml, p=0.113) and mean Dpd levels in the two studied (natural menopause 6.8 +/- 2.3 vs surgical menopause 7.8 +/- 3.4 mM, p=0.213). CONCLUSION: IGF-1 was significantly lower in natural menopause as compared with surgical menopause, but no significant difference was found in IGFBP-3, Ost, and Dpd levels
Biomarkers* ; Carrier Proteins* ; Female ; Humans ; Insulin* ; Insulin-Like Growth Factor Binding Protein 3 ; Insulin-Like Growth Factor Binding Proteins* ; Insulin-Like Growth Factor I ; Menopause* ; Osteocalcin* ; Plasma ; Radioimmunoassay

No abstract available.
Insulin-Like Growth Factor Binding Proteins* ; Kidney Failure, Chronic*

Endotoxins ; Humans ; Insulin-Like Growth Factor Binding Proteins ; Liver Cirrhosis

The insulin-like growth factor-I(IGF-I) is a hormone that has growth stimulation and metabolic effects. Insulin-like growth factor binding proteins (IGFBPs) were known to be the most important factors that affect bioavailability of IGF. Thereby, the changes of IGFBPs may affect the bioavailability of IGF-I. Because growth hormone/IGF system may be affected by dialysis therapy, the changes of GH, IGF-1, IGFBPs levels after dialysis therapy can affect the bioavailability of IGF. To evaluate the changes of serum levels of IGF-I and IGFBP-3 after long-term dialysis therapy, we measured the serum IGF-I and IGFBP-3 levels in the patients on hemodialysis and on peritoneal dialysis. Eight patients undergoing peritoneal dialysis, 10 patients undergoing hemodialysis, and age-matched 10 normal control patients were studied. In patients on hemodialysis, the mean serum level of IGF-I before hemodialysis was 90.6+/-9.0 nanogram/mL, and after long-term hemodialysis was 130.9+/-31.0 nanogram/milliliter. The mean serum level of IGFBP-3 before hemodialysis was 14,549+/-7,815 microgram/liter, and after long-term hemodialysis was 5,726+/-883 microgram/liter. There were no significant changes of serum IGF-I and IGFBP-3 levels after long-term hemodialysis therapy. In patients on peritoneal dialysis, the mean serum level of IGF-I before peritoneal dialysis was 169.8+/-20.5 nanogram/milliliter, and after long-term peritoneal dialysis was 242.6+/-37.6 nanogram/mL. The mean serum level of IGFBP- 3 before peritoneal dialysis was 10,272+/-885 microgram/liter, and after ling-term peritoneal dialysis was 8,604+/-1,721 microgram/liter. There were no significant changes of serum IGF-I and IGFBP-3 levels after long-term peritoneal dialysis. We found that the level of IGF-1 before hemodialysis was lower then that of normal control group and the level of IGFBP-3 before hemodialysis or peritoneal dialysis was higher then that of normal control group. Our results suggested that the blood levels of growth hormone, IGF-I and IGFBP-3 may not be significantly affected by long-term dialysis therapy.
Biological Availability ; Dialysis* ; Growth Hormone* ; Humans ; Insulin-Like Growth Factor Binding Protein 3 ; Insulin-Like Growth Factor Binding Proteins ; Insulin-Like Growth Factor I ; Peritoneal Dialysis ; Renal Dialysis

PURPOSE: The insulin like growth factors (IGFs) circulate complexed to IGF-binding proteins(IGFBPs). IGFBP-3 is the major circulating IGFBP and is found primarily as a 150 kDa complex which contains an acid labile subunit(ALS), IGFBP-3, and IGF-I or IGF-II and is considered to be growth hormone(GH) dependent. In this study, we measured serum IGF-I, IGFBP-3 and 150 kDa levels in sera of growth hormone deficient children(GHD) before and after GH treatment respectively to clarify the utility of these factors as a diagnostic marker for GHD and to observe the alterations of these factors according to GH treatment. METHODS: Measurement of serum IGF-I, IGFBP-3 and 150 kDa complex were performed in 10 children with complete growth hormonr deficiency(cGHD), in 6 children with partial growth hormone deficiency(pGHD) and in 10 normal healthy subjects. Serum IGF-I was measured by radioimmunoassay (RIA). IGF-I was seperated from IGFBPs by Sephadex G-50 acid chromatography. Serum IGFBP-3 was assessed by Western ligand blot(WLB) analysis as described by Hossenlopp with minor modifications. To evaluate alterations of different molecular size classes of IGF-BP complexes according to GH treatment, WLB was done after neutral size-exclusion chromatography using Sephacryl S-200. RESULTS: 1) The serum IGF-I level in children with GHD was significantly lower than that of control subjects(96.2+/-40.1 ng/ml vs 147.5+/-37.9 ng/ml)(p<0.01). 2) The serum IGF-I level in children with cGHD was significantly lower than that of normal subjects (p<0.01). But four of the 10 children with cGHD the IGF-I levels were distributed within the range of -2 S.D.. The serum IGF-I level in children with pGHD was also lower than that of normal subjects but there was no statistical significance between two groups(P>0.05). 3) The serum IGFBP-3 level is markedly decreased in 9 of 10 children with cGHD, but only in 2 of 6 children with pGHD which was measured by WLB method. 4) The serum IGF-I level after GH treatment was increased significantly in children with GHD(138.7+/-49.2 ng/ml vs 78.7+/-23.4 ng/ml)(p<0.01). The serum IGFBP-3 level was also increased after GH treatment as similar pattern. 5) The marked decrement of serum IGFBP-3 level in children with cGHD was explained as the result of decline in the 150 kDa IGFBP complex, and after GH treatment 150 kDa complex was increased; in the 150 kDa IGFBP complex, free IGF-I binding sites were increased. CONCLUSIONS: The serum levels of IGF-I, IGFBP-3 and 150 kDa complex in children with cGHD were decreased significantly, but in children with pGHD these changes were not observed as prominant as cGHD. These findings suggest that the measurments of serum IGF-I, IGFBP-3 level may be useful not only in the diagnosis of GHD but also differentiate cGHD from pGHD and the serum IGFBP-3 level may be more sensitive for diagnosing GHD even though each test by itself has a limited diagnostic accuracy as a single test.
Binding Sites ; Child* ; Chromatography ; Diagnosis ; Growth Hormone* ; Humans ; Insulin* ; Insulin-Like Growth Factor Binding Protein 3 ; Insulin-Like Growth Factor Binding Proteins ; Insulin-Like Growth Factor I ; Insulin-Like Growth Factor II ; Radioimmunoassay ; Somatomedins

Background: The serum levels of total insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 reflect endogenous growth hormone (GH) secretion in healthy children. Free form of IGF-I which is suggested to have more potent biological action than complex form of IGF-I. The aim of this study is to investigate the serum levels of free IGF-I and its clinical value in healthy children. METHODS: Serum levels of total IGF-I and IGFBP-3 were determined in 494 healthy children (248 boys and 246 girls) by RIA and IRMA. Serum level of free IGF-I was determined in 206 healthy children (103 boys and 103 girls) by IRMA. RESULTS: The free IGF-I level increased with age in both sex. The free IGF-I level increased continuously between 7 and 15 years of age in boys, but decrement was noted after 14 years of age in girls. Serum total IGF-I level also increased with age in similar pattern of that of free IGF-I. There were no significant differences of mean values of the ratio of free IGF-I/total IGF-I in relation to age in both sex. And there were significant correlations between the level of free IGF-I and total IGF-I and the ratio of total IGF-I/IGFBP-3, respectively. CONCLUSION: In healthy children, serum free IGF-I increased with age in both sex and high free IGF-I level may play an important role in pubertal growth spurt. Our results suggest that the increased serum free IGF-I level in puberty may reflect changes in total IGF-I rather than IGFBP-3. But free IGF-I does not have more clinical value than total IGF-I because of no significant differences of mean values of the ratio of free IGF-I/total IGF-I in relation to age.
Carrier Proteins ; Child ; Growth Hormone ; Humans ; Insulin-Like Growth Factor Binding Protein 3 ; Insulin-Like Growth Factor I ; Puberty

PURPOSE: This study was undertaken to compare the growth promoting effect between patients with idiopathic growth hormone deficiency(IGHD) and those with organic growth hormone deficiency(OGHD). METHODS: Seventeen children with GH deficiency were divided into two groups: 7 IGHD and 10 OGHD including craniopharyngioma(5), sella germinoma(1), prolactinoma(1), Langerhans cell histiocytosis(1) and postirradiation(1). Diagnosis of GHD was made on the basis of two growth hormone provocative tests, serum IGF-1 & IGFBP 3 level, and bone age. Both groups were treated with recombinant human growth hormone(0.6-0.8IU/Kg/week) for 2 years and auxological parameters (height velocity, height SDS CA(standard deviation score for chronologic age)) were analyzed during 2 years of treatment by using KIGS 4.0 software program. RESULTS :The mean pretreatment height velocity in both groups did not differ statistically(2.6+/-.8cm/yr in IGHD vs 2.5+/-.9cm/yr in OGHD: p>0.05). However, height velocity after 2 years of growth hormone treatment was significantly greater in IGHD group than in OGHD group(9.0+/-.3cm/yr in IGHD vs 7.2+/-.8cm/yr in OGHD: P<0.05). The height SDS for CA has improved remakably during 2 years of growth hormone treatment; -3.46 SDS before treatment to -1.53 SDS in IGHD group, -2.3 SDS to -0.5 SDS in OGHD group. CONCLUSION: Growth hormone replacement therapy has remakably improved height velocity and height SDS for CA in both groups during the 2 years of the treatment. However, the height velocity in OGHD group was significantly less than in IGHD, indicating that additional factors such as malnutrition, associated multiple hormone deficiencies, spinal irradiation and sexual precocity might significantly hamper the growth promoting effect in OGHD group during growth hormone treatment.
Child* ; Diagnosis ; Growth Hormone* ; Humans ; Insulin-Like Growth Factor Binding Proteins ; Insulin-Like Growth Factor I ; Malnutrition

PURPOSE:Insulin-like growth factors, IGF- I and IGF-II, are proteins that promote cellular growth and differentiation of the various organs including the kidney. These peptides circulate in serum bound to specific carrier proteins, called IGF binding proteins(IGFBPs). The IGFs are produced in most organs but liver is believed to be the principal source of circulating IGF-I. We studied the correlation of serum IGF-I and IGFBP-2 pattern with aging. METHODS:Sera were collected from 320 healthy population who were grouped according to age. IGF-I was seperated from IGFBPs by Sephadex G-50 acid chromatography. We measured serum IGF-I and IGFBP-2 by using radioimmuno-assay (RIA) and immunoradiometric assay (IRMA) respectively. RESULTS:Serum IGF-I levels were quite low in early childhood, rising slowly and reaching a peak during puberty and a significant decline(P<00.01) during adulthood. The age-dependent pattern of serum IGFBP-2 levels shows a pattern opposite to that of IGF-I which are high at birth, decline by late puberty and increase again with aging. CONCLUSION: Our results demonstrate the alteration of serum IGF-I and IGFBP- 2 pattern with aging. These data suggests that when these tests are performed in the clinic, their interpretation should be based upon age specific criteria.
Adolescent ; Aging* ; Carrier Proteins ; Chromatography ; Humans ; Immunoradiometric Assay ; Insulin-Like Growth Factor Binding Protein 2 ; Insulin-Like Growth Factor Binding Proteins ; Insulin-Like Growth Factor I ; Insulin-Like Growth Factor II ; Intercellular Signaling Peptides and Proteins ; Kidney ; Liver ; Parturition ; Peptides ; Puberty

The insulin-like growth factor binding protein (IGFBP) family is a critical component of the insulin-like growth factor (IGF) system which regulate the biological actions of the IGFs and may also be capable of IGF-independent actions. To date, seven distinct IGFBPs have been described. Among these IGFBPs, IGFBPs-1-6 bind IGFs with high affinity, while only IGFBP-7 binds with low affinity. Recently, we have demonstrated that connective tissue growth factor (CTGF) also binds IGFs with low affinity, suggesting that a family of low-affinity IGFBPs, distinct from the high-affinity members, may exist, and together these constitute an IGFBP superfamily. IGFBPs have various biological roles. IGFBPs act not only as a carrier proteins, but also as a modulators of IGF actions by involving in IGF ligand-receptor interactions through influences on both the bioavailability and distribution of IGFs in the extracellular environment. In addition, some IGFBPs (IGFBPs-1, -3, and -5) appears to have intrinsic activity independent of IGFs. This review will focus on recent studies on the biological roles of IGFBPs in IGF-dependent and IGF-independent modes.
Biological Availability ; Carrier Proteins ; Connective Tissue Growth Factor ; Humans ; Insulin-Like Growth Factor Binding Proteins* ; Somatomedins